The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 25, 2017

Filed:

Apr. 02, 2013
Applicants:

Consiglio Nazionale Delle Ricerche, Rome, IT;

Università Cattolica Del Sacro Cuore, Milan, IT;

Inventors:

Maria Cristina De Rosa, Rome, IT;

Francesco Ria, Rome, IT;

Bruno Giardina, Rome, IT;

Gianfranco Ferraccioli, Rome, IT;

Davide Pirolli, Rome, IT;

Chiara Nicolo′, Sutri, IT;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 207/08 (2006.01); C07D 401/04 (2006.01); A61K 31/4025 (2006.01); A61K 31/4439 (2006.01); C07D 407/12 (2006.01); A61K 31/343 (2006.01); A61K 31/40 (2006.01); A61K 31/403 (2006.01); C07D 409/12 (2006.01); C07D 207/06 (2006.01); C07D 209/86 (2006.01); C07D 209/88 (2006.01); C07D 307/91 (2006.01); C07C 251/86 (2006.01); A61K 31/165 (2006.01); A61K 31/381 (2006.01);
U.S. Cl.
CPC ...
C07D 407/12 (2013.01); A61K 31/165 (2013.01); A61K 31/343 (2013.01); A61K 31/381 (2013.01); A61K 31/40 (2013.01); A61K 31/403 (2013.01); A61K 31/4439 (2013.01); C07C 251/86 (2013.01); C07D 207/06 (2013.01); C07D 207/08 (2013.01); C07D 209/86 (2013.01); C07D 209/88 (2013.01); C07D 307/91 (2013.01); C07D 401/04 (2013.01); C07D 409/12 (2013.01); C07C 2103/18 (2013.01);
Abstract

The T cells specific to human collagen type II, one of the possible autoantigens, have a crucial role in the development of rheumatoid arthritis in the context of HLA-DR4. The protein-protein interactions between the T cell receptor (TCR) and the type II collagen linked to the allele MHC of class II HLA-DR4 may thus represent the target for the development of new drugs against rheumatoid arthritis. Using computational virtual screening techniques, families of pharmacologically active molecules have been identified that interfere with the TCR/collagen ll-MHCII interaction. The compounds identified here open up new possibilities in the treatment of rheumatoid arthritis.


Find Patent Forward Citations

Loading…